Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siCSF2#2
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siCSF2#2 is a specific small interfering RNA (siRNA) sequence designed to silence the expression of Colony-stimulating factor 2 (CSF2), also known as Granulocyte-macrophage colony-stimulating factor (GM-CSF). In preclinical research, particularly concerning colorectal cancer, siCSF2#2 is utilized to investigate the role of CSF2 in mediating resistance to chemotherapeutic agents such as 5-fluorouracil (5-FU) and oxaliplatin. By targeting and promoting the degradation of CSF2 mRNA, siCSF2#2 reduces CSF2 protein levels, which subsequently inhibits the Notch signaling pathway. This inhibition has been shown to sensitize colorectal cancer cells to chemotherapy, suggesting that CSF2 is a viable target for overcoming drug resistance in this malignancy.
- Other names
- si-CSF2-2si-CSF-2-2si-CSF 2-2CSF2 siRNA #2
02
Targets
GM-CSF (Granulocyte-macrophage colony-stimulating factor)
Beyond the preview
Go deeper on siCSF2#2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siCSF2#2.